RPRX - Repros Therapeutics Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development12,75324,11627,107
Selling General and Administrative4,5675,0875,437
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-17,320-29,203-32,544
Income from Continuing Operations
Total Other Income/Expenses Net47119
Earnings Before Interest and Taxes-17,273-29,192-32,535
Interest Expense---
Income Before Tax-17,273-29,192-32,535
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-17,273-29,192-32,535
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-17,273-29,192-32,535
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-17,273-29,192-32,535